556 related articles for article (PubMed ID: 33960511)
1. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
[TBL] [Abstract][Full Text] [Related]
3. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A; Armand C; Murteira S; Cochran J; François C
Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
8. [The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson's disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital].
Szász JA; Constantin V; Fazakas PA; Blényesi E; Grieb LG; Balla A; Sárig M; Szegedi K; Bartha EN; Szatmári S
Orv Hetil; 2017 Dec; 158(51):2023-2028. PubMed ID: 29250969
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
10. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
Jann MW
Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
[TBL] [Abstract][Full Text] [Related]
11. Treatment Strategies in Early Parkinson's Disease.
Marsili L; Marconi R; Colosimo C
Int Rev Neurobiol; 2017; 132():345-360. PubMed ID: 28554414
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
13. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
14. [Dopamine agonists in Parkinson's disease therapy - 15 years of experience of the Neurological Clinics from Tîrgu Mureș. A cross-sectional study].
Szász JA; Viorelia C; Mihály I; Biró I; Péter C; Orbán-Kis K; Szatmári S
Ideggyogy Sz; 2019 May; 72(5-6):187-193. PubMed ID: 31241263
[TBL] [Abstract][Full Text] [Related]
15. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
16. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacotherapeutic treatment options in Parkinson's disease.
Rezak M
Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Sy MAC; Fernandez HH
Neurotherapeutics; 2020 Oct; 17(4):1331-1338. PubMed ID: 32935299
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
Shimbo T; Hira K; Takemura M; Fukui T
Pharmacoeconomics; 2001; 19(8):875-86. PubMed ID: 11596839
[TBL] [Abstract][Full Text] [Related]
20. Initiating dopaminergic treatment in Parkinson's disease.
Lang AE; Marras C
Lancet; 2014 Sep; 384(9949):1164-6. PubMed ID: 24928806
[No Abstract] [Full Text] [Related]
[Next] [New Search]
